Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)
China · Delayed Price · Currency is CNY 11.30
-0.36 (-3.09%)
Sep 10, 2026, 1:45 PM CST
SHE:301211 Revenue
Hubei Biocause Heilen Pharmaceutical had revenue of 127.35M CNY in the quarter ending June 30, 2026, with 5.84% growth. This brings the company's revenue in the last twelve months to 466.05M, up 6.22% year-over-year. In the year 2025, Hubei Biocause Heilen Pharmaceutical had annual revenue of 453.31M with 1.67% growth.
Revenue (ttm)
466.05M
Revenue Growth
+6.22%
P/S Ratio
10.45
Revenue / Employee
489.55K
Employees
952
Market Cap
4.87B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 453.31M | 7.44M | 1.67% |
| Dec 31, 2024 | 445.86M | -217.16M | -32.75% |
| Dec 31, 2023 | 663.03M | 148.11M | 28.76% |
| Jan 1, 2023 | 514.91M | -25.71M | -4.76% |
| Jan 1, 2022 | 540.62M | -52.30M | -8.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Yabao Pharmaceutical Group | 2.25B |
| Hunan Fangsheng Pharmaceutical | 1.87B |
| Fuan Pharmaceutical (Group) | 1.66B |
| Guizhou Sanli Pharmaceutical Co.,Ltd | 1.56B |
| Zhejiang AngLiKang Pharmaceutical CO.,LTD. | 1.33B |
| Beijing Beilu Pharmaceutical | 1.29B |
| Hunan Hansen Pharmaceutical | 1.01B |
| ChengDu ShengNuo Biotec | 911.15M |